The market is driven by advanced healthcare infrastructure, strong adoption of home-based diagnostics, and widespread use in decentralized clinical trials. Rising chronic disease prevalence and continuous innovation in patient-friendly, low-volume blood collection technologies are further supporting market growth.
Microsampling & minimally invasive blood collection is a method of collecting small blood samples using low-pain techniques like finger-prick or microneedles for easy, patient-friendly diagnostic testing. The U.S. microsampling & minimally invasive blood collection market is growing due to strong healthcare infrastructure, high adoption of home-based diagnostics, and the increasing use in decentralized clinical trials. Rising chronic disease prevalence, demand for patient-friendly testing, and continuous advancements in low-volume blood collection technologies are further accelerating market expansion across hospitals, laboratories, and research organizations.
The global microsampling & minimally invasive blood collection market size was estimated at USD 2.4 billion in 2025 and is predicted to increase from USD 2.71 billion in 2026 to approximately USD 8 billion by 2035, expanding at a CAGR of 12.8% from 2026 to 2035.
The U.S. microsampling & minimally invasive blood collection market is expected to grow due to strong demand for patient-centric diagnostics, expansion of decentralized clinical trials, and rapid adoption of at-home sampling technologies. Continuous innovation by key players and increasing investments in digital and remote healthcare solutions are further strengthening market expansion.
| Parameter | 2024 | 2025 |
| Clinical trial adoption (%) | 48% | 61% |
| Home-based sampling usage (%) | 35% | 52% |
| Diagnostics application usage (%) | 39% | 55% |
| Capillary sampling utilization (%) | 44% | 58% |
| Decentralized trial participation (%) | 41% | 63% |
The increase in all key indicators from 2024 to 2025 reflects strong market acceleration driven by rising adoption of home-based sampling, expansion of decentralized clinical trials, and higher use in diagnostics and research. Growing preference for minimally invasive techniques and improved patient compliance further supported widespread integration of advanced microsampling technologies.
The microsampling devices segment dominated the U.S. microsampling & minimally invasive blood collection market with a share of 62% in 2025 due to its high accuracy, ease of use, and strong suitability for patient-friendly and home-based blood collection. Increasing demand in diagnostics, clinical trials, and chronic monitoring, along with rapid adoption of minimally invasive technologies, strengthened its leading position.
The dried blood spot (DBS) segment led the U.S. microsampling & minimally invasive blood collection market with a 34% share in 2025 due to its sampling collection process, low cost, and ability to preserve samples for a long period without complex storage requirements. Its strong use in newborn screening, infectious disease testing, and remote diagnostics, along with easy transport and minimal blood volume needs, supported its leading position.
The diagnostics segment led the U.S. microsampling & minimally invasive blood collection market with a 42% share in 2025 due to the rising need for early disease detection, routine health screening, and effective chronic disease monitoring. Increasing use of microsampling in hospitals, diagnostic laboratories, and home testing kits, along with faster results, patient convenience, and growing awareness of preventive healthcare, is driving strong market adoption.
The hospital & clinics segment held a dominant position in the market with a share of 36% in 2025 due to high patient inflow, frequent diagnostic testing, and strong adoption of minimally invasive blood collection methods. Availability of skilled healthcare professionals, advanced infrastructure, and increasing focus on patient comfort and rapid diagnostics further strengthened their dominance in the market.
The direct sales segment dominated the U.S. microsampling & minimally invasive blood collection market with a revenue share of 48% in 2025 due to a strong relationship between manufacturers and large healthcare buyers such as hospitals, diagnostic laboratories, and research institutes. This channel ensures bulk purchasing, customized solutions, reliable supply, and better after-sales support, making it the preferred distribution method for microsampling and minimally invasive blood collection products.
Leading companies in the market, including Becton, Dickinson and Company, Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, dominate through strong portfolios of capillary blood collection systems, diagnostic solutions, and sample handling technologies. Specialized players such as Tasso, Inc. and Neoteryx are driving innovation in at-home and wearable microsampling devices, while emerging biotech and diagnostics firms are expanding rapidly in decentralized testing and remote patient monitoring solutions, supporting continuous market growth and adoption.
By Product Type
By Technique
By Application
By End User
By Distribution Channel
